Squamous cell carcinomas (SCCs) represent a minority of new oesophageal cancers in the United States, but remain the dominant histologic subtype of oesophageal cancer worldwide and a significant cause of mortality ([@bib27]). Various combinations of chemotherapy, radiotherapy and surgery have been evaluated in the management of this disease. Preoperative chemotherapy or chemoradiotherapy (CRT) followed by surgical resection and definitive chemoradiation are all standard options for this disease ([@bib22]). However, despite aggressive therapeutic approaches, outcomes remain poor. Better risk stratification using prognostic and predictive markers would allow for tailoring therapeutics to the biology of the individual tumour. One such approach is the use of ^18^F-fluorodeoxyglucose-positron emission tomography (^18^F-FDG-PET) imaging to measure the metabolic activity in tumours, which represents a combination of proliferative activity and number of viable cells. The standard uptake value (SUV) is a semi-quantitative measure of ^18^FDG uptake and metabolic activity, and has been shown to be predictive of survival in many cancer types.

FDG-PET imaging is a routine component of initial workup for oesophageal cancer and is of proven value in staging, response assessment and detection of recurrence ([@bib11]; [@bib2]). Moreover, FDG-PET has substantial promise as a tool to assess response to therapy and as an imaging biomarker to help guide therapy in oesophageal cancer. Because PET imaging can be obtained at various time points in the treatment process, serial scans may provide additional prognostic information based on metabolic response. Baseline pretreatment maximum SUV (SUVmax) levels have been correlated with survival among patients treated with definitive chemoradiation ([@bib21]) or surgical resection ([@bib23]; [@bib4]; [@bib16]; [@bib12]).

Post-CRT FDG-PET imaging has been evaluated in several studies, however, the prognostic utility of SUVmax after CRT remains controversial due to difficulties in distinguishing post-radiotherapy inflammation from residual viable tumour([@bib8]; [@bib13]; [@bib19]; [@bib6]).

Another approach has been to evaluate change in SUVmax from baseline to post treatment. In several studies of patients with oesophageal adenocarcinoma in Germany, where the typical treatment consisted of neoadjuvant chemotherapy, followed by surgical resection, a decline in SUV after one cycle of chemotherapy was found to be a prognostic marker. Patients who were found to be metabolic responders, based on a \>35% decline in SUVmax after one cycle of chemotherapy, experienced better progression-free survival (PFS) and overall survival (OS) than metabolic non-responders ([@bib25]). These data have led to further evaluation of the approach of early PET imaging assessment after induction chemotherapy and determination of the efficacy of the regimen based on metabolic response in a multicentre, cooperative group study (Cancer and Leukemia Group B trial 80803).

Nonetheless, because of differences in tumour biology and prognosis ([@bib5]), the data from oesophageal adenocarcinomas cannot be extrapolated to SCC. Thus, the aim of our study was to validate the 35% decline in SUVmax after chemotherapy as prognostic for outcome in oesophageal SCC patients treated with induction chemotherapy followed by CRT. In addition, we report outcomes of an aggressive approach of CRT in oesophageal SCC patients, the majority of whom also received induction chemotherapy, and investigated the use of SUVmax as well as a quantitative metabolic parameter, metabolic tumour volume (MTV), obtained at serial imaging sessions before, during and after treatment as potential imaging biomarkers for response assessment and prognostication.

Materials and Methods
=====================

Patient and treatment characteristics
-------------------------------------

After obtaining a waiver of authorisation from the Institutional Review Board, we identified 57 patients with oesophageal SCC treated with CRT with curative intent using intensity-modulated radiotherapy (IMRT) at our institution between 2007 and 2011. For staging (2002 AJCC classification), patients underwent endoscopic ultrasound and biopsy, diagnostic CT of chest and abdomen with intravenous contrast, and ^18^F-FDG-PET/CT.

Fifty-two patients received induction chemotherapy before CRT and 10 patients underwent surgery following CRT (see below). Chemotherapy regimens were recorded as induction or concurrent therapy and classified either as platinum/irinotecan regimen, platinum/taxane regimen, 5-fluorouracil-based regimen or other ([Table 1](#tbl1){ref-type="table"}). Five patients did not receive induction chemotherapy: four patients did not have baseline FDG-avid tumours; one patient had advanced age with multiple comorbidities, which was deemed ineligible for induction chemotherapy.

All patients underwent CT-based simulation on a Discovery ST PET/CT (GE Healthcare, Waukesha, WI, USA) for RT in the supine position, using intravenous and oral contrast to better delineate the target volume and were immobilised in an alpha cradle (except cervical oesophageal SCC patients who had a custom facemask). Four-dimensional CT scans were used to track tumour motion, and respiratory gating was used to deliver radiotherapy only during the expiratory phase of the respiratory cycle for patients with distal oesophageal and GE junction tumours. The clinical tumour volume (CTV) included the primary tumour, all involved lymph nodes on PET and CT imaging, peri-oesophageal nodes and mediastinal nodes ∼4--5 cm above and below the GTV. The coeliac nodes were included in the CTV for lower oesophageal tumours and supraclavicular nodes were included for tumours above the carina. Organs at risk included lungs, heart, spinal cord, liver and kidneys. Intensity-modulated radiotherapy was delivered with dynamic multi-leaf collimation on a Varian accelerator (Varian Medical Systems, Inc., Palo Alto, CA, USA). Median dose to the primary tumour was 5600 cGy ([Table 1](#tbl1){ref-type="table"}). A subset of 10 patients underwent Ivor Lewis oesophagectomy. Seven patients had surgery at a median of 2.65 months (range: 1.43--3.67 months) following CRT with curative intent. Another 3 patients had surgery following local recurrence at a median of 11.1 months (range: 5.13--17.5 months) after CRT.

PET imaging
-----------

Patients underwent PET/CT at three time points: (1) for pretreatment staging (*n*=51); (2) post-induction chemotherapy (*n*=41); and (3) after the end of chemoradiotherapy (*n*=40), using Siemens Biograph (Siemens/CPS Innovations, Knoxville, TN, USA) or Discovery LS, 690, ST or STE PET/CT scanners (GE Medical Systems). All the patients were not imaged on the same scanner but all were state-of-the-art equipment. Similar to our clinical scans, all patients fasted for 6 h before ^18^F-FDG injection (12 mCi). The standard uptake time was 60--80 min. For repeat scans, uptake times were within ∼10--15 min of baseline uptake times. Unenhanced CT was performed from the skull base to the upper thighs. The PET emission scans were obtained afterwards from the base of skull to the upper thighs. Images were reconstructed with and without attenuation correction. The average time from completion of IMRT to post-CRT PET was 74 days and Median of 42 days (range: 19--631). All PET/CT scans were analysed retrospectively on a Hermes workstation using software version 4.7-B (Hermes Medical Solutions AB, Stockholm, Sweden). The average liver SUV for baseline PET, post-induction PET and post-CRT PET were 2.0, 2.2 and 2.1, respectively. The SUVs were normalised to body weight ((kBq per ml activity in region)/(kBq injected activity per body mass in g)). The SUVmax is the maximum SUV in any voxel within the tumour ([@bib24]). The highest SUVmax value was in the primary tumour. We then calculated the MTV, defined as the volume of FDG-avid disease including all voxels that contain activity equal to or higher than 42% of the maximum tumour activity. There is no general agreement regarding what threshold to choose, different groups use different approaches. This value was chosen based on published data completed at our institution ([@bib7]). [Table 2](#tbl2){ref-type="table"} summarises the PET metrics at the three different scans.

Follow-up
---------

All patients were followed at regular intervals after completion of therapy. Follow-up generally consisted of a physical exam and laboratory testing every 3 months and imaging with CT of the chest and abdomen every 6 months for the first 2 years and then annually until 5 years after the completion of treatment. Oesophagogastroduodenoscopy (EGD) was performed every 6 months for 2 years and then annually. Patients treated with definitive CRT who did not undergo surgery usually underwent more frequent EGD to monitor for local recurrence. All patients were followed until date of death or last follow-up.

Statistical analysis
--------------------

Patient characteristics presented by median and range for continuous variables, and by frequency for categorical variables. Summary statistics of PET parameters are presented by mean, s.d. and range. The OS, DFS, LRFS and DMFS rates were evaluated from the three different scan time points (baseline, post induction and post CRT) with results specifying from which scan a clinical outcome is being assessed. There was no significant delay from diagnosis to patients getting scanned. Only patients still alive at scan or having PET measurements were used in the analysis of the PET parameters.

Time to LRFS was calculated from the date of scan to the date of first event (LR or death) or last follow-up. Time to DMFS was calculated from the date of scan to the date of first event (DM or death) or until last follow-up. Overall survival was calculated from the date of scan to the date of death or last follow-up. Disease-free survival was calculated from the date of scan to the date of disease recurrence (LR, DM or death). For all four survival end points, patients alive without the event of interest were censored. Kaplan--Meier and Cox regression were used to evaluate the relationship between PET parameters and the four outcomes. Hazard ratio (HR) is equivalent to the odds of a specified clinical end point occurring with every one incremental increase in the PET parameter of interest. The percent changes in the PET parameters were calculated from baseline to post-induction chemotherapy, from baseline to post CRT and from post induction to post CRT. On the basis of the pre-established 35% SUVmax decrease from baseline to post-induction PET, we analysed this cutoff to define PET responders (⩾35%) and non-responders (\<35%). All PET parameters were assessed as continuous variables.

Variables that were significant in the univariate analyses were evaluated in a multivariate model ([@bib18]). *P*-values \<0.05 were considered significant. All analysis was done using R version 3.0.0 with *survival* package ([cran.r-project.org](http://www.cran.r-project.org)).

To identify a potential threshold SUVmax at the various scanning time points that best separated DFS, a minimally selected log-rank test was used to find an optimal cut point for baseline and post-induction SUVmax. In this approach, selected values of the variable of interest were examined as candidates for the cut point. The value chosen was one that best separated patient outcomes according to a minimum *P*-value. The *P*-value was adjusted for multiple testing.

Results
=======

Patient characteristics
-----------------------

A total of 57 patients with oesophageal SCC who underwent CRT at our institution were analysed, of whom 52 received induction chemotherapy before CRT. Of these 57 patients, 7 patients underwent surgical resection following CRT with curative intent. Patient and tumour characteristics are shown in [Table 1](#tbl1){ref-type="table"}. These patients had clinical stage T1N1 or T2-4N0-1 without evidence of metastatic disease.

Clinical outcomes
-----------------

With a median follow-up of 23.6 months from end of radiotherapy, the median OS for the entire cohort of 57 patients was 2.9 years. The 3-year OS rate from date of baseline PET for the entire cohort was 47% ([Figure 1A](#fig1){ref-type="fig"}). At the time of analysis, 21 (37%) patients remained alive with median follow-up of 4.4 years from end of radiotherapy for this subset of patients. Median DFS for entire cohort of 57 patients was 1.5 years. Three-year DFS from date of baseline PET for the cohort was 40% ([Figure 1B](#fig1){ref-type="fig"}). Median DMFS time for all 57 patients was 2.0 years with 3-year rate of DMFS from initial PET of 44%. Twenty-one of the 57 patients (37%) developed DM.

Local disease recurrence was evaluated in the subset of 50 patients who did not undergo curative surgery following completion of CRT. Seventeen of the 50 patients (34%) developed LR. Median LRFS was 2.0 years with 3-year LRFS from date of baseline PET of 36%. Three of these 17 patients underwent surgical resection with a median time of 11.1 months from end of radiotherapy to surgery.

PET imaging findings
--------------------

A total of 57 patients (100%) underwent a baseline PET/CT; of these 51 patients (91%) had analysable baseline imaging, while 5 had SUVmax values from the outside report. One patient underwent outside baseline imaging without an analysable or reported SUV value. All regions of interest were manually redrawn in consensus with two nuclear medicine physicians (HS and LO). Forty patients of the entire cohort (70%) also underwent post-induction PET/CT and 41 patients of the entire cohort (72%) underwent PET/CT after completion of CRT. Scan data for one patient in the CRT group was not available but the reported SUVmax value was used. Post-induction and post-CRT scans for 17 and 16 patients, respectively, were not in our PACS and their outside reports were not in the electronic medical records. A total of 30 (53%) patients had scans at all 3 time points. [Table 2](#tbl2){ref-type="table"} shows data for SUVmax and MTV at all 3 time points.

PET prognosticators of outcome
------------------------------

### Percent change in SUVmax and MTV

Of the 38 patients with both baseline and post-induction chemotherapy PET scans, there were 25 PET 'responders\' and 13 PET 'non-responders\' based on the pre-specified cutoff of 35% decrease in SUVmax from baseline. The responders had a significantly longer median survival and 3-year OS, as calculated from date of post-induction PET, in comparison with non-responders (3-year OS 64% *vs* 15% *P*=0.004). Furthermore, PET responders had a significantly greater DFS, as calculated from date of post-induction PET (3-year DFS 52% *vs* 15.4% *P*=0.021) and DMFS, as calculated from date of post-induction PET (3-year DMFS 60% *vs* 15.4% *P*=0.011). Of note, the cutoff of 35% in SUVmax did not correlate with LRFS (*P*=0.15). Percent change in SUVmax from baseline to post-CRT PET or post-induction to post-CRT PET did not correlate with OS, LRFS, DMFS or DFS.

Percent change of MTV from baseline to post-induction therapy scan was not significant for any clinical outcomes. In addition, percent change in MTV between baseline and post-CRT scans as well as between post-induction and post-CRT scans were not associated with OS, LRFS, DMFS or DFS.

### Baseline SUVmax and MTV

In univariate analysis, lower baseline SUVmax (HR 1.093; *P*=0.001) and MTV (HR 1.018; *P*=0.002) were significantly associated with better OS ([Table 3](#tbl3){ref-type="table"}). Both baseline PET metrics were also significantly associated with DFS and DMFS. Local recurrence-free survival was associated with decreased baseline SUVmax (HR 1.080; *P*=0.001) and MTV (HR 1.013; *P*=0.025) ([Table 3](#tbl3){ref-type="table"}).

On multivariate analysis for baseline PET/CT parameters, SUVmax trended towards significance for OS (HR 1.074; *P*=0.059) as well as DFS (HR 1.07; *P*=0.052) when compared with MTV. The SUVmax remained prognostic for LRFS (HR 1.091; *P*=0.012) and DMFS (HR 1.081; *P*=0.031) when compared with MTV ([Table 4](#tbl4){ref-type="table"}).

Utilising a minimally selected log-rank test, we found the optimal cutoff for baseline SUVmax that best separated DFS with a minimum *P*-value was 17.1 (*P*=0.014). The 3-year DFS, as calculated from baseline PET, was 7% for baseline SUVmax \>17.1, and 52% for baseline SUVmax ⩽17.1 ([Figure 2A](#fig2){ref-type="fig"}).

### Post-induction chemotherapy SUVmax and MTV

In univariate analysis, lower SUVmax (HR 1.108; *P*\<0.001) and MTV (HR 1.02; *P*=0.001) were significantly associated with better OS. These same parameters were also significantly associated with DFS, LRFS and DMFS ([Table 3](#tbl3){ref-type="table"}).

On multivariate analysis, SUVmax was only significant for DMFS (HR 1.108; *P*=0.046) in comparison with MTV ([Table 4](#tbl4){ref-type="table"}).

The optimal post-induction SUVmax cutoff for DFS was 9.09 (*P*=0.019). The 3-year DFS, as calculated from post-induction PET, was 7% for post-induction SUVmax \>9.09, and 56% for post-induction SUVmax ⩽9.09 ([Figure 2B](#fig2){ref-type="fig"}).

### Post-CRT SUVmax and MTV

In univariate analysis of post-CRT PET parameters, only MTV was prognostic for OS (HR 1.089; *P*=0.046). None of the PET metrics were significant for DFS. With regards to LRFS and DMFS, only SUVmax was significant ([Table 3](#tbl3){ref-type="table"}). Owing to low number of events, multivariate analysis of post-CRT parameters was not feasible ([Table 4](#tbl4){ref-type="table"}).

Discussion
==========

The management of oesophageal SCCs remains controversial with multiple therapeutic combinations and no established prognostic or predictive factors to guide treatment decisions. There are limited data on the use of PET imaging to prognosticate outcomes or to predict treatment response specifically in the oesophageal SCC population, however, the use of percent change in SUVmax after induction chemotherapy has been reported in several trials of patients with oesophageal and gastroesophageal junction adenocarcinomas ([@bib25]; [@bib15]; [@bib10]). In this study, we validated the use of a SUVmax response of ⩾35% decline from baseline to after induction chemotherapy as a prognostic marker for improved OS and DFS in patients with oesophageal SCC.

Weber *et al* initially evaluated the use of serial PET imaging in patients with adenocarcinoma of the gastroesophageal junction who received neoadjuvant chemotherapy and demonstrated that 'metabolic responders\' after 2 weeks of chemotherapy had improved histopathologic response and greater OS compared with 'metabolic non-responders\' 'metabolic responders\' were defined as patients with ⩾35% decline in FDG SUVmax value from baseline to 2 weeks after neoadjuvant chemotherapy ([@bib25]). This observation was confirmed in the MUNICON (Metabolic response evalUatioN for Individualisation of neoadjuvant Chemotherapy in oesOphageal and oesophagogastric adeNocarcinoma) trial in which 'metabolic non-responders\' to induction chemotherapy went to immediate surgery rather than continuing with the 3 months of preoperative chemotherapy ([@bib15]). The median DFS in the 'metabolic non-responders\' who discontinued ineffective chemotherapy and went directly to surgery appeared to be better than in previous studies where these patients completed the 3 months of neoadjuvant chemotherapy (26 *vs* 18 months). Ilson *et al* also confirmed the PET scan response cutoff point of 35% after induction chemotherapy was associated with improved pathologic complete response (pCR) rates (32% *vs* 4% *P*=0.009) and DFS (24 *vs* 7.7 months; *P*=0.02) ([@bib10]). In this prospective study, 55 patients with oesophageal cancer, predominantly (75%) adenocarcinomas, were treated with induction cisplatin and irinotecan (4 treatments over 5 weeks) followed by a post-induction PET scan and then continued on with chemoradiation with concurrent cisplatin, irinotecan and 50.4 Gy. Thirty-nine patients also underwent oesophagectomy.

Although these data were generated primarily in patients with oesophageal adenocarcinomas, we explored whether this cutoff of 35% decrease in SUVmax from baseline to post induction could be extrapolated to the population of oesophageal SCC patients. Indeed, the *a priori* defined cutoff of 35% decrease proved significance with respect to OS (*P*=0.0041) and DFS (*P*=0.021) ([Figure 3A and B](#fig3){ref-type="fig"}); thus confirming a similar prognostic ability among varying histological subtypes.

We also evaluated outcomes of an aggressive approach of induction chemotherapy followed by chemoradiation in this retrospective study of a relatively homogeneous cohort of patients with oesophageal SCC. The use of induction chemotherapy followed by combined chemoradiation is not the global standard of care for this disease and has not been compared with chemoradiotherapy alone in the context of a phase III trial. However, in this group of 57 oesophageal SCC patients treated with CRT, 52 of whom received induction chemotherapy, we demonstrate that the outcomes are good with a 3-year OS and DFS of 47% and 40%, respectively. The use of induction chemotherapy has several potential advantages as the particular chemotherapy regimen can be tested for efficacy using PET response in the primary tumour after induction therapy without the confounding effect of the concurrent radiotherapy. This allows for early changes in systemic therapy, which can then be administered during radiotherapy. The use of PET scans to direct preoperative therapy in patients with oesophageal and GEJ adenocarcinomas is being examined in the Cancer and Leukemia Group B trial 80803, now closed to accrual. In this randomised phase II study, patients undergo a baseline PET scan and are randomised to either FOLFOX (folinic acid--fluorouracil--oxaliplatin) or carboplatin and paclitaxel followed by a post-induction chemotherapy PET scan. The metabolic non-responders, based on the 35% cutoff, crossover to the alternative chemotherapy regimen during combined chemoradiation while the metabolic responders continue on with the same chemotherapy.

Apart from analysing the use of the 35% change in SUVmax from baseline to post-induction chemotherapy, we also evaluated the prognostic potential of SUVmax at single time points and the percent change from baseline or post induction to post CRT. We found that on UVA, baseline and post-induction SUVmax were important prognostic parameters for OS, DFS LRFS, and DMFS. In this analysis, we found that a baseline SUVmax of \>17 and a post-induction SUVmax of \>9 were both predictive of worse outcomes. Previous studies have demonstrated the prognostic and predictive values of these parameters, however they have focused predominantly on adenocarcinoma histology ([@bib26]; [@bib9]; [@bib17]). Because of differences in histology, one cannot extrapolate published data on AC to SCC. Analysis of percent change in SUVmax from baseline or post-induction PET to post-CRT PET did not appear to have any prognostic value.

Interestingly, post-CRT SUVmax was prognostic for LRFS and DMFS in this study. The use of a post-CRT prognostic SUVmax parameter may allow for stratification of patients who would benefit from surgery after CRT, though the prognostic ability of post-CRT SUVmax requires further validation. The benefit of surgical resection after CRT in oesophageal SCC has been questioned as two randomised trials of CRT with or without surgery failed to demonstrate a benefit for the addition of surgery ([@bib3]; [@bib20]). Moreover, recent data from a large, randomised trial of surgery alone *vs* preoperative CRT followed by surgery for oesophageal cancer demonstrated a pCR rate of 49% in patients with oesophageal SCC after preoperative chemoradiation ([@bib22]). This high pCR rate for the patients with oesophageal SCC suggests that surgery may not be necessary in a subset of SCC patients who respond well to CRT. Unfortunately, response assessment after CRT is generally limited using almost any modality, including PET, CT, endoscopic ultrasound or even biopsy, because of treatment-associated inflammation and fibrosis. Thus, further data are needed to verify the findings in this study.

In addition to our analysis of SUVmax, we assessed MTV, a volumetric PET parameter. We also identified on UVA, both baseline and post-induction MTV to be prognostic for OS, DFS, LRFS and DMFS. However, on subsequent multivariate analysis, MTV at baseline and post induction was not independently prognostic for any clinical outcomes when compared with SUVmax. In part, this loss of prognostication of MTV may reflect the inherent dependence of these volumetric parameters on the value of SUVmax and the predetermined threshold. In calculating MTV, a predetermined percentage of the primary tumour SUVmax affects the calculated volume. As such, relatively low SUVmax values may falsely incorporate non-malignant tissues in the MTV volume, thus reducing the prognostic value of MTV. Our data differ from a recent study from France, which demonstrated that MTV at baseline was a major prognostic factor for DFS and OS in a cohort of 67 oesophageal SCC patients ([@bib14]).

When evaluating the prognostic significance of post-CRT MTV, we discovered a significant correlation existed only for OS. In contrast, analysis of percent change in MTV between any two PET time points revealed no prognostic correlation with clinical outcomes.

Various limitations exist in this current study, including its retrospective nature and the relatively small sample size; however, the latter is a consequence of the rarity of SCC in the United States. Another potential concern is the uncertain impact of using induction chemotherapy before CRT on the outcome for SCC. The use of induction chemotherapy remains controversial in head and neck SCC and in anal SCC, has been shown to negatively impact outcomes ([@bib1]). The typical schedule of induction chemotherapy in our cohort consisted of 1--2 cycles, thus not delaying initiation of radiotherapy significantly or presumably negatively affecting outcomes. In conclusion, a cutoff of ⩾35% decrease in SUVmax from baseline to post-induction PET can be extrapolated from oesophageal adenocarcinoma to SCC and provides strong prognostic information in patients with SCC undergoing multimodality therapy. With the potential ability to tailor individual therapies based on PET response, prospective clinical trials are necessary to further validate this approach in the oesophageal SCC population.
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![(**A**) OS for all patients. (**B**) DFS for all patients.](bjc2015416f1){#fig1}

![(**A**) DFS probability of patients with a baseline SUVmax ⩽17.1 (solid line) compared with patients with SUVmax \>17.1 (dashed line; *P*=0.014). (**B**) DFS probability of patients with a post-induction SUVmax ⩽9.09 (solid line) compared with patients with SUVmax \>9.09 (dashed line; *P*=0.019).](bjc2015416f2){#fig2}

![(**A**) OS by metabolic response status (*P*=0.004). (**B**) DFS by metabolic response status (*P*=0.02).](bjc2015416f3){#fig3}

###### Clinical and treatment characteristics

  **Parameters**                            **No. of patients (*****n*****=57)**
  ---------------------------------------- --------------------------------------
  **Age (years)**                          
  Range                                                    36--95
  Median                                                     67
  **Gender**                               
  Male                                                       36
  Female                                                     21
  **Karnofsky performance status (KPS)**   
  Range                                                    70--90
  Median                                                     80
  **Baseline haemoglobin**                 
  Median, g dl^−1^ (range)                             12.6 (8.7--17)
  **Post-induction haemoglobin**           
  Median, g dl^−1^ (range)                            11.7 (8.3--15.9)
  **Site**                                 
  Upper oesophagus                                           16
  Middle oesophagus                                          23
  Lower oesophagus                                           15
  GE                                                         3
  **Tumour length on initial EUS (cm)**    
  Range                                                   0.3--15
  Median                                                    5.0
  **Histological differentiation**         
  Poorly differentiated                                      25
  Moderately differentiated                                  24
  Well differentiated                                        2
  Unknown                                                    6
  **TNM staging**                          
  Tx                                                         3
  T1                                                         2
  T2                                                         9
  T3                                                         41
  T4                                                         2
  N0                                                         11
  N1                                                         45
  N2                                                         1
  **Radiation therapy details**            
  4500 cGy                                                   1
  5040--5200 cGy                                             25
  5600 cGy                                                   24
  6000 cGy                                                   7
  Underwent surgery                                          10
  **Induction chemotherapy**               
  Platinum and irinotecan regimen                            35
  Platinum and taxane regimen                                14
  Fluorouracil-containing regimen                            3
  Did not receive chemotherapy                               5
  **Concurrent chemotherapy**              
  Platinum and irinotecan regimen                            29
  Platinum and taxane regimen                                15
  Fluorouracil-containing regimen                            8
  Other                                                      5

Abbreviations: EUS=endoscopic ultrasound; TNM=extent of primary tumour-lymph nodes-metastases based on 2002 AJCC classification.

###### PET metric values at the three imaging time points

                      **SUVmax**     **MTV (cm**^**3**^)
  ---------------- ---------------- ---------------------
  Baseline          13.3±7 (2--32)    19.0±22 (1--122)
  Post induction    8.8±6 (2--27)     15.7±23 (1--114)
  Post CRT          4.1±2 (2--11)       7.1±5 (2--26)

Abbreviations: CRT=chemoradiotherapy; MTV=metabolic tumour volume; PET=positron emission tomography; SUVmax=maximum standard uptake value.

Data are mean±s.d. (range in parentheses).

###### Prognostic value of PET metrics -- univariate analysis

                              **Hazard ratio for OS (*****P*****-value)** **(number of patients)**   **Hazard ratio for LRFS (*****P*****-value)** **(number of patients)**   **Hazard ratio for DFS (*****P*****-value)** **(number of patients)**   **Hazard ratio for DMFS (*****P*****-value)** **(number of patients)**
  -------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------------------- ------------------------------------------------------------------------
  Baseline SUVmax                                  1.09 (*P*=0.001) (*n*=56)                                               1.08 (*P*=0.001) (*n*=49)                                                1.09 (*P*=0.001) (*n*=56)                                               1.11 (*P*\<0.001) (*n*=56)
  Post-induction CT SUVmax                         1.11 (*P*\<0.001) (*n*=40)                                              1.07 (*P*=0.010) (*n*=36)                                                1.10 (*P*=0.001) (*n*=40)                                               1.13 (*P*\<0.001) (*n*=40)
  Post-CRT SUVmax                                         NS (*n*=41)                                                      1.40 (*P*=0.004) (*n*=32)                                                       NS (*n*=38)                                                      1.15 (*P*=0.043) (*n*=40)
  Baseline MTV                                     1.02 (*P*=0.002) (*n*=51)                                               1.01 (*P*=0.025) (*n*=46)                                                1.02 (*P*=0.008) (*n*=51)                                               1.02 (*P*=0.001) (*n*=51)
  Post-induction CT MTV                            1.02 (*P*=0.001) (*n*=40)                                               1.01 (*P*=0.025) (*n*=36)                                                1.02 (*P*=0.003) (*n*=40)                                               1.02 (*P*=0.001) (*n*=40)
  Post-CRT MTV                                     1.09 (*P*=0.046) (*n*=40)                                                      NS (*n*=31)                                                              NS (*n*=37)                                                             NS (*n*=39)

Abbreviations: CT=chemotherapy; CRT=chemoradiotherapy; DFS=disease-free survival; DMFS=distant metastasis-free survival; LRFS=local recurrence-free survival; MTV=metabolic tumour volume; NS=not significant; OS=overall survival; PET=positron emission tomography; SUVmax=maximum standard uptake value.

###### Prognostic value of PET metrics -- multivariate analysis

                              **Hazard ratio for OS (*****P*****-value)** **(number of patients)**   **Hazard ratio for LRFS (*****P*****-value)** **(number of patients)**   **Hazard ratio for DFS (*****P*****-value)** **(number of patients)**   **Hazard ratio for DMFS (*****P*****-value)** **(number of patients)**
  -------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------------------- ------------------------------------------------------------------------
  Baseline SUVmax                                         NS (*n*=51)                                                      1.09 (*P*=0.012) (*n*=46)                                                       NS (*n*=51)                                                      1.08 (*P*=0.031) (*n*=51)
  Post-induction CT SUVmax                                NS (*n*=40)                                                             NS (*n*=36)                                                              NS (*n*=40)                                                      1.11 (*P*=0.046) (*n*=40)
  Post-CRT SUVmax                                        Not applicable                                                          Not applicable                                                          Not applicable                                                           Not applicable
  Baseline MTV                                            NS (*n*=51)                                                             NS (*n*=46)                                                              NS (*n*=51)                                                             NS (*n*=51)
  Post-induction CT MTV                                   NS (*n*=40)                                                             NS (*n*=36)                                                              NS (*n*=40)                                                             NS (*n*=40)
  Post-CRT MTV                                           Not applicable                                                          Not applicable                                                          Not applicable                                                           Not applicable

Abbreviations: CT=chemotherapy; CRT=chemoradiotherapy; DFS=disease-free survival; DMFS=distant metastasis-free survival; LRFS=local recurrence-free survival; MTV=metabolic tumour volume; NS=not significant; OS=overall survival; PET=positron emission tomography; SUVmax=maximum standard uptake value.

[^1]: Co-authors.
